PPARG and Hepatic steatosis: In mice, butyrate supplementation was shown to prevent insulin resistance and obesity [40], via a PPARγ-dependent switch from lipogenesis to fat oxidation [41], and to reduce high-fat diet-induced intestinal barrier dysfunction and metabolic alterations, including hepatic steatosis [42].